These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 36889303

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB, Churg AM, Cheung S, Dacic S.
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [Abstract] [Full Text] [Related]

  • 7. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Sato A, Tsujimura T, Ueda H, Makihata S, Kato F, Iwasaki A, Nabeshima K.
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.
    Lynggård LA, Panou V, Szejniuk W, Røe OD, Meristoudis C.
    J Am Soc Cytopathol; 2022 Nov; 11(6):385-393. PubMed ID: 35945149
    [Abstract] [Full Text] [Related]

  • 9. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A, Prabhakaran S, Pulford E, Hocking AJ, Godbolt D, Ziad F, Pandita A, Wessels A, Hussey M, Russell PA, Klebe S.
    Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301
    [Abstract] [Full Text] [Related]

  • 10. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z, Kepenekian V, Fenouil T, Glehen O, Villeneuve L, Isaac S, Hommell-Fontaine J, Benzerdjeb N.
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [Abstract] [Full Text] [Related]

  • 11. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y, Hamasaki M, Matsumoto S, Yoshimura M, Sato A, Tsujimura T, Kamei T, Kawahara K, Nabeshima K.
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
    Chapel DB, Hornick JL, Barlow J, Bueno R, Sholl LM.
    Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
    [Abstract] [Full Text] [Related]

  • 14. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [Abstract] [Full Text] [Related]

  • 15. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS, Tekin E, Ak G, Metintaş M, Metintaş S, Dündar E.
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [Abstract] [Full Text] [Related]

  • 16. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [Abstract] [Full Text] [Related]

  • 17. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y, Hamasaki M, Matsumoto S, Yoshimura M, Sato A, Tsujimura T, Kamei T, Kawahara K, Iwasaki A, Nabeshima K.
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A, Sheffield BS, Galateau-Salle F.
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.